Eli Lilly has entered a strategic co-development partnership with Hong Kong-listed Insilico Medicine. The collaboration utilizes Insilico’s artificial intelligence platform to identify and design new pharmaceutical products.
The agreement carries a potential total value of $2.75 billion. While some reports estimated the deal at $2 billion, the funding will support Insilico’s ongoing drug pipeline.
The partnership focuses initially on a GLP-1 drug for diabetes. Eli Lilly secured exclusive rights for the development and commercialization of this treatment.